PDS BIOTECHNOLOGY CORPORATION PDSB 深 滬
等待開盤 10-04 09:30:00 美东时间
1.02
0.000
0.00%
華盛通- 最 高1.05
- 今 開1.04
- 成交量 26.75万股
- 最 低 1.01
- 昨 收 1.02
- 總市值 4662.42万
- 52周最高 3.48
- 市盈率 靜 --
- 換手率 0.59%
- 52周最低 0.8505
- 委 比 52.63%
- 總股本 4571.00万
- 歷史最高 17.85
- 量 比 1.02
- 振 幅 3.92%
- 歷史最低 0.615
- 每 手 1
- 風險率 1.04%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多PDS Biotechnology Announces VERSATILE-002 Trial Success
The latest announcement is out from PDS Biotechnology ( ($PDSB) ). On September...
09-18 21:19
PDS Biotech Reports 29.5-Month Median Overall Survival In Phase 2 Trial For Advanced Head And Neck Cancer; Says Encouraging Efficacy Signal Observed In Difficult To Treat Category Of Advanced Head And Neck Cancer Patients
First combination therapy to report 29.5 months of Median Overall Survival (mOS); Standard of care Keytruda® (pembrolizumab) alone (10.8 months) and Keytruda® + chemotherapy (12.3 months) in patients with CPS
09-18 20:47
PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population
A clinical trial sub-analysis by PDS Biotechnology Corporation reveals that PDS0101 (Versamune® HPV) combined with Keytruda® (pembrolizumab) significantly improves survival in patients with low PD-L1 expression (CPS 1-19) in advanced head and neck squamous cell cancer (HNSCC). The median overall survival (mOS) for this cohort reached 29.5 months, compared to 10.8 months with Keytruda® alone and 12.3 months with Keytruda® plus chemotherapy. This i...
09-18 12:45
【一周科技动态】AWS新叙事，AMZN马上新高？GOOGL如何成为本周大赢家
涨跌纷纭——一周大科技表现 本周宏观主线： 投资者对9月的历史性弱势保持警惕，该月往往是股市表现最差的月份。重大事件包括Russell指数的重构初步公告，以及...
09-05 15:39
PDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
PDS Biotechnology Corporation will participate in the 27th Annual H.C. Wainwright Global Investment Conference on September 8-10, 2025, in New York and virtually. CEO Frank Bedu-Addo, Ph.D., and CFO Lars Boesgaard will meet with investors. PDS Biotech, a late-stage immunotherapy company, is advancing its lead program PDS0101 (Versamune® HPV) in combination with pembrolizumab for advanced HPV16-positive head and neck cancers.
09-02 12:00
英伟达迎来一群劲敌
原标题：英伟达迎来一群劲敌 近期发布的超以太网（Ultra Ethernet，简称UE）1.0规范，为未来人工智能（AI）和高性能计算（HPC）系统定义了一套...
09-01 16:17
英伟达韩松团队新作：具有后神经架构搜索的高效语言模型
时令 发自 凹非寺 量子位 | 公众号 QbitAI 英伟达开源又放大招了！ 韩松团队推出了一款全新的基于后神经架构搜索的高效语言模型——Jet-Nemotr...
08-26 16:11
PDS Biotechnology Announces Promising Phase 2 Trial Results
PDS Biotechnology ( ($PDSB) ) just unveiled an announcement. On August 25, 2025...
08-25 20:58
PDS Biotechnology Reports Median Overall Survival Of 39.3 Months In HPV16-Positive Head And Neck Cancer Patients
Median Overall Survival (mOS) of 39.3 months in patients with CPS ≥ 1 – best published result with standard of care pembrolizumab or pembrolizumab + chemotherapy is 17.9 months*VERSATILE-003 Phase 3 trial in
08-25 20:34
PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer
PDS Biotech announced final topline survival data from the VERSATILE-002 Phase 2 trial, showing a median overall survival (mOS) of 39.3 months in HPV16-positive recurrent/metastatic head and neck squamous cell cancer (HNSCC) patients treated with PDS0101 + pembrolizumab. This compares favorably to the best published mOS of 17.9 months with standard pembrolizumab or pembrolizumab + chemotherapy. The trial enrolled 53 patients, with durable surviva...
08-25 12:30
